ViaNautis Bio Ltd closes US$25m Series A financing
Intracelluar drug delivery specialist ViaNautis Bio Ltd will use US$25 raised in a Series A financing to push applications of its bionic nanoparticle platform polyNaut.
Intracelluar drug delivery specialist ViaNautis Bio Ltd will use US$25 raised in a Series A financing to push applications of its bionic nanoparticle platform polyNaut.
The 29th BIO-Europe in Munich was able to boast record figures: around 6,000 participants for the first time, over 30,000 partnering meetings for the first time at what was already […]
Belgian amyloid fibrils specialist Amyl Therapeutics SA has got a �11n cash injection by existing and new investors and the Walloon region to advance its therapeutic platform. <br /> <br /><br […]
German Evotec SE and Boston-based Dewpoint Therapeutics Inc have entered into a strategic partnership in oncology.<br /><br />
Pierre Fabre Laboratories SA has extended its global partnership with Atara Biotherapeutics, licencing tabelecleucel commercialisation rights for Northern America and beyond.
Biotech companies in Scotland�s thriving bio-based manufacturing have been invited to apply for up to �1m funding within the Launchpad programme.
Non-profit foundation BioInnovation Institute (BII) has unveiled its latest commitment to driving innovation and growth within the life science sector. Six promising companies will receive crucial financial support through BIIs Venture House programme.
At a council meeting, a majority of EU agriculture ministers have supported the draft regulation on new genomic technologies (NGT) proposed by the EU Commission in early July.
German researchers have developed a new way to detect the about 300 cullin-RING ligases (CRLs) which specifically trigger destruction of specific proteins in the cell.
According to Swiss bioethicists, deregulation of genetic engineering rules for plants optimised through targeted mutation and cisgenetics will make little contribution to climate protection by 2050.